Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, Hepatitis C, clinical trials

Zymo Drug Kills Hep C Virus

Luke Timmerman 4/24/09

ZymoGenetics (NASDAQ: ZGEN), a Seattle biotech company, and partner Bristol-Myers Squibb said today that a drug they are co-developing for hepatitis C was able to kill the virus with minimal side effects in a small four-week study. The trial looked at pegylated interferon lambda on its own, or in combination with a standard ribavirin treatment. The full data was presented at the European Association for the Study of the Liver meeting in Copenhagen, Denmark.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Reader Comments

  • deborah anderson
    5/13/09 10:55 pm

    help me

  • larry yarbrough
    7/5/09 5:24 pm

    I do hope this treatment works and it’s on the market soon. The side effects
    of current treatment of pegintron nearly killed my wife.

  • Ray Patterson
    11/12/09 1:45 am

    Please help me. I could not complete the standard treatment because of the nasty side effects. It almost killed me. I will volunteer to be a test subject for this promising new drug. Please help.

    Ray Patterson
    rptexas@gmail.com

  • Luke Timmerman
    11/12/09 10:38 am

    Ray—you can find more information about an ongoing clinical trial of the ZymoGenetics drug at this link below.

    http://clinicaltrials.gov/ct2/show/NCT01001754?term=IL-29&rank=2

Links to This Post

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.